BTIG Lifts Nektar Therapeutics Price Target to $151, Citing REZPEG Data and Pipeline Catalysts
BTIG raised its price target on Nektar Therapeutics to $151 from $118 while maintaining a Buy rating, identifying the company as a top pick for the first half of 2026. The upgrade follows an updated market model for REZPEG in atopic dermatitis that assumes first-line use in advanced-treatment eligible patients, and it leans on encouraging 52-week R…